The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.
 
Charles S. Fuchs
Consulting or Advisory Role - Agios; Bayer; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Sanofi; Taiho Pharmaceutical
 
Kohei Shitara
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Maria Di Bartolomeo
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Bayer
Speakers' Bureau - Lilly; Roche
Research Funding - Sanofi
 
Salah-Eddin Al-Batran
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Roche; SERVIER
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
David H. Ilson
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda
 
Ian Chau
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi
 
Michel Ducreux
Honoraria - Lilly; Servier
Consulting or Advisory Role - Amgen; Celgene; Ipsen; Lilly; Merck Serono; Novartis; Roche; Servier
Speakers' Bureau - Bayer; Celgene; Ipsen; Merck KGaA; Roche
Research Funding - Pfizer; Roche
Travel, Accommodations, Expenses - Celgene; Ipsen; Merck Serono; Roche
Other Relationship - Sandoz (I)
 
Guillermo Ariel Mendez
No Relationships to Disclose
 
Alejandro Molina Alavez
No Relationships to Disclose
 
Daisuke Takahari
Honoraria - Chugai Pharma; Lilly; Titan Medical; Yakult Pharmaceutical
Consulting or Advisory Role - Lilly; Titan Medical
Research Funding - Titan Medical
 
Wasat Mansoor
No Relationships to Disclose
 
Jill Lacy
Consulting or Advisory Role - Celgene; LEK; Sirtex Medical
Travel, Accommodations, Expenses - Lilly
 
Vera Gorbunova
Consulting or Advisory Role - Amgen; Bayer; Eisai; Lilly
Speakers' Bureau - Amgen; Bayer; Eisai
 
David Ferry
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patents relating to work with employer Eli Lilly; Patents relating to work with employer Eli Lilly
 
Mayukh Das
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Manish A. Shah
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Lilly/ImClone (Inst); Merck (Inst); Sanofi/Regeneron (Inst)